TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00422864
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
Study: NCT00950859
Drug: GSK1349572 (Cohort I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg once daily
Study: NCT00950859
Drug: GSK1349572 (Cohort II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg twice daily
Study: NCT03398083
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill capsule
Study: NCT00478218
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
Study: NCT03062540
Drug: Placebo SL Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
Study: NCT03184467
Drug: Normal Saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
Study: NCT01900717
Drug: LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02446899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (IV)
Study: NCT02871908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02074410
Drug: OMS643762
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02074410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03184467
Drug: GV1001 1.12 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
Study: NCT02325414
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous infusion of zoledronic acid 5 mg.
Study: NCT02325414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) infusion to match zoledronic acid
Study: NCT02469545
Drug: Crystalline cellulose powder
Normalized name: cellulose Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
Study: NCT00330967
Drug: 20% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipid infusion
Study: NCT04591600
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed
Study: NCT04211909
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet orally once daily.
Study: NCT04211909
Drug: SOF/VEL/VOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100/100 mg FDC tablet orally once daily.
Study: NCT00721513
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01652534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Pill
Study: NCT01035801
Drug: IN-105
Normalized name: POLOXAMER 105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial Oral Insulin
Study: NCT01019083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given according to randomization list
Study: NCT01019083
Drug: Zinc Sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc Sulphate will be given according to randomization list
Study: NCT03103334
Drug: Methotrexate Biodim®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
Study: NCT00798161
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01255683
Drug: oral corticosteroid taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
Study: NCT02541396
Drug: Wafermine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 or 70 mg ketamine in a sublingual wafer
Study: NCT02541396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule or placebo wafer
Study: NCT02170415
Drug: Protective analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.~For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day.
Study: NCT02283762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-titration
Study: NCT00540332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
Study: NCT00202878
Drug: ezetimibe/simvastatin
Normalized name: EZETIMIBE/SIMVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
Study: NCT00202878
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
Study: NCT00202878
Drug: Placebo for simvastatin 40 mg
Normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one or two tablets orally daily
Study: NCT00202878
Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet orally daily.
Study: NCT00685568
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
Study: NCT01409811
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01098513
Drug: GSK1349572 formulation AW
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.
Study: NCT02273804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken orally following to the same dose regimen according to theoretical weight
Study: NCT04621227
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg single dose
Study: NCT01745497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent volume of liquid with similar color and taste.
Study: NCT00241189
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00329355
Drug: sumatriptan succinate/naproxen sodium
Normalized name: sumatriptan succinate/naproxen sodium 10 mg-60 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04292418
Drug: Tacrolimus capsule , mycophenolic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
Study: NCT00785382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose Placebo
Study: NCT00295373
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01297491
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
Study: NCT01805791
Drug: HMPL-004 1800 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg TID (total dose 1800 mg/day) for 56 days (8 weeks).
Study: NCT01805791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).
Study: NCT01805791
Drug: HMPL-004 2400 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg TID (total dose 2400 mg/day) for 56 days (8 weeks).
Study: NCT01829321
Drug: GLPG0974
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule in the morning and 1 capsule in the evening with food during 28 days
Study: NCT01829321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule in the morning and 1 capsule in the evening with food during 28 days
Study: NCT02434029
Drug: Placebo orodispersible tablet twice daily
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01243580
Drug: AG200-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200-15 is a transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
Study: NCT02004678
Drug: DS-1150b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00312195
Drug: Placebo to match BTDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match buprenorphine transdermal patch applied for 7-day wear.
Study: NCT02951182
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03655249
Drug: Aerosoltherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
Study: NCT02858505
Drug: 27 mg elemental iron
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02858505
Drug: 54 mg elemental iron
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03841331
Drug: Matching Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets
Study: NCT03089905
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
Study: NCT03739125
Drug: CKD-501 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
Study: NCT03739125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
Study: NCT01348516
Drug: KM-023
Approvals — FDA: no, EMA: no, PMDA: no
Description: -KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
Study: NCT01348516
Drug: Placebo for KM-023
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
Study: NCT02100696
Drug: Etrozulimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
Study: NCT02100696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
Study: NCT00424541
Drug: SPP100 (aliskiren)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00492128
Drug: Losartan/amlodipine or losartan/hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
Study: NCT01120717
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules for inhalation, delivered by an SDDPI
Study: NCT01120717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules for inhalation, delivered by an SDDPI
Study: NCT04411030
Drug: ASTX660
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: capsule; Route of administration: oral
Study: NCT01995656
Drug: Placebo - Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01995656
Drug: LY3108743 - Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01995656
Drug: Placebo - Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01995656
Drug: LY3108743 - Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00110721
Drug: GM-CT-01 plus 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
Study: NCT02121080
Drug: REGN2222(SAR438584)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02121080
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03237325
Drug: SGX942
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
Study: NCT03237325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
Study: NCT01993238
Drug: Pre-treatment analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
Study: NCT00734318
Drug: Flutiform 250/10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00734318
Drug: Flutiform 50/5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00734318
Drug: Flixotide pMDI 250 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02332044
Drug: Erdos, Talion
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule 300mg and tablet 10mg
Study: NCT02210494
Drug: Secretrol
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00653926
Drug: ropivacaine, ketorelac and epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
Study: NCT05429385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose, intravenous infusion
Study: NCT01858935
Drug: ND-L02-s0201 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion.
Study: NCT01858935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion.
Study: NCT02967224
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT03616301
Drug: Clavamox
Normalized name: Clavamox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, manufactured by Pharmtechnology LLC, Belarus
Study: NCT03616301
Drug: Augmentin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, marketed by CJSC GlaxoSmithKline Trading, Russia
Study: NCT04522830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.
Study: NCT03733301
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as standard-of-care.
Study: NCT00483119
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
Study: NCT00937859
Drug: SER120
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER120
Study: NCT00937859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04668066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given intravenously or subcutaneous
Study: NCT00707941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children \< 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25
Study: NCT02246465
Drug: RXI-109
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01134705
Drug: Placebo Nasal Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA Vehicle Aerosol
Study: NCT01125449
Drug: Ascorbic acid (vitamin C)
Normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
Study: NCT01215097
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day
Study: NCT01779466
Drug: Placebo (not active)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03196362
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of placebo will be given twice daily
Study: NCT04562428
Drug: Xiang Sha Liu Jun Zi Decoction dry powder
Normalized name: Calagel Reformulated Jun 2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei
Study: NCT04562428
Drug: XSLJZ Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: XSLJZ Placebo
Study: NCT01562093
Drug: corticosteroid nasal spray
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
Study: NCT01562093
Drug: placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
Study: NCT02203773
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
Study: NCT04198051
Drug: adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form、dosage and frequency： Gastric cancer was given the SOX regimen (oxaliplatin + tegafur regimen,oxaliplatin 130mg/m2 intravenous infusion, the 1st day; tegafur 80mg/ m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle) or XELOX regimen (oxaliplatin + capecitabine regimen，oxaliplatin 130mg/m2 intravenous infusion, the 1st day; capecitabine 1000mg/m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle).~Colon cancer was given the XELOX regimen (the dosage、frequency and administration are the same as the gastric cancer) or FOLFOX regimen (oxaliplatin + calcium folinate + fluorouracil regimen，oxaliplatin 85mg/m2 intravenous infusion, the 1st day; calcium folinate 400 mg/m2 intravenous infusion, the 1st day; fluorouracil 400 mg/m2 intravenous infusion, the 1st day, then 1200 mg/m2/d × 2d continuous intravenous infusion，every 14 days is one cycle).~Duration：through chemotherapy completion，about six months.
Study: NCT02146534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be taken PO BID
Study: NCT01614691
Drug: SPARC1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT01614691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00566397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo